Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
-
April
-
May
-
June
-
July
-
August
-
September
- Oktober -
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
- 2024
Oktober 2024 - 71 products
L
IP
Winrevair 45 mg
5956.94
6419.60
10 %
Lyophilisate and solvent: Sotaterceptum 45 mg
MSD Merck Sharp &
Dohme AG
B / SL
FB
G
L
IP
Winrevair 45 mg
2
11913.87
12531.45
10 %
Lyophilisate and solvent: Sotaterceptum 45 mg
MSD Merck Sharp &
Dohme AG
B / SL
FB
G
L
IP
Winrevair 60 mg
7942.58
8456.90
10 %
Lyophilisate and solvent: Sotaterceptum 60 mg
MSD Merck Sharp &
Dohme AG
B / SL
FB
G
L
IP
Winrevair 60 mg
2
15885.16
16605.95
10 %
Lyophilisate and solvent: Sotaterceptum 60 mg
MSD Merck Sharp &
Dohme AG
B / SL
FB
G
IP
Vyvgart 400 mg/20ml
PR
PR
k.A.
Concentrate for infusion: Efgartigimodum Alfa 400mg / 20ml
argenx Switzerland SA
A
FB
G
Bupropion-Mepha XR 150 mg
30
PR
PR
k.A.
Delayed release tablets: Bupropioni Hydrochloridum 150 mg
Mepha Pharma AG
B
FB
G
Bupropion-Mepha XR 300 mg
30
PR
PR
k.A.
Delayed release tablets: Bupropioni Hydrochloridum 300 mg
Mepha Pharma AG
B
FB
G
Co-Losartan Spirig HC 50
mg/12.5 mg
28
PR
PR
k.A.
Coated tablets: 2 Active Agents
Spirig HealthCare AG
B
FB
G
Co-Losartan Spirig HC 50
mg/12.5 mg
98
PR
PR
k.A.
Coated tablets: 2 Active Agents
Spirig HealthCare AG
B
FB
G
Co-Losartan Spirig HC 100
mg/12.5 mg
28
PR
PR
k.A.
Coated tablets: 2 Active Agents
Spirig HealthCare AG
B
FB
G
Co-Losartan Spirig HC 100
mg/12.5 mg
98
PR
PR
k.A.
Coated tablets: 2 Active Agents
Spirig HealthCare AG
B
FB
G
Co-Losartan Spirig HC 100
mg/25 mg
28
PR
PR
k.A.
Coated tablets: 2 Active Agents
Spirig HealthCare AG
B
FB
G
Co-Losartan Spirig HC 100
mg/25 mg
98
PR
PR
k.A.
Coated tablets: 2 Active Agents
Spirig HealthCare AG
B
FB
G
CM
Eletriptan Spirig HC 40 mg
4
PR
PR
k.A.
Coated tablets: Eletriptanum 40 mg
Spirig HealthCare AG
B
FB
G
CM
Eletriptan Spirig HC 40 mg
6
PR
PR
k.A.
Coated tablets: Eletriptanum 40 mg
Spirig HealthCare AG
B
FB
G
CM
Eletriptan Spirig HC 40 mg
20
PR
PR
k.A.
Coated tablets: Eletriptanum 40 mg
Spirig HealthCare AG
B
FB
G
CM
Eletriptan Spirig HC 80 mg
6
PR
PR
k.A.
Coated tablets: Eletriptanum 80 mg
Spirig HealthCare AG
B
FB
G
CM
Eletriptan Spirig HC 80 mg
20
PR
PR
k.A.
Coated tablets: Eletriptanum 80 mg
Spirig HealthCare AG
B
FB
G
IP
Filspari 200 mg
30
PR
PR
k.A.
Coated tablets: Sparsentanum 200 mg
Vifor (International)
Inc.
B
FB
G
IP
Filspari 400 mg
30
PR
PR
k.A.
Coated tablets: Sparsentanum 400 mg
Vifor (International)
Inc.
B
FB
G
IP
Filspari 400 mg
90
PR
PR
k.A.
Coated tablets: Sparsentanum 400 mg
Vifor (International)
Inc.
B
FB
G
Lytgobi 4 mg
21
PR
PR
k.A.
Coated tablets: Futibatinibum 4 mg
Taiho Oncology Europe
GmbH
A
FB
G
Lytgobi 4 mg
28
PR
PR
k.A.
Coated tablets: Futibatinibum 4 mg
Taiho Oncology Europe
GmbH
A
FB
G
Lytgobi 4 mg
35
PR
PR
k.A.
Coated tablets: Futibatinibum 4 mg
Taiho Oncology Europe
GmbH
A
FB
G
IP
Yuvanci 10 mg/40 mg
30
PR
PR
k.A.
Coated tablets: 2 Active Agents
Janssen-Cilag AG
B
FB
G
IP
Pomalidomid-Teva Mepha 1 mg
14
PR
PR
k.A.
Capsules: Pomalidomidum 1 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 1 mg
21
PR
PR
k.A.
Capsules: Pomalidomidum 1 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 2 mg
14
PR
PR
k.A.
Capsules: Pomalidomidum 2 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 2 mg
21
PR
PR
k.A.
Capsules: Pomalidomidum 2 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 3 mg
14
PR
PR
k.A.
Capsules: Pomalidomidum 3 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 3 mg
21
PR
PR
k.A.
Capsules: Pomalidomidum 3 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 4 mg
14
PR
PR
k.A.
Capsules: Pomalidomidum 4 mg
Teva Pharma AG
A
FB
G
IP
Pomalidomid-Teva Mepha 4 mg
21
PR
PR
k.A.
Capsules: Pomalidomidum 4 mg
Teva Pharma AG
A
FB
G
CM
Allerxtin Sandoz 20 mg
10
PR
PR
k.A.
Tablets: Bilastinum 20 mg
Sandoz
Pharmaceuticals AG
D
FB
G
CM
Allerxtin Sandoz 20 mg
30
PR
PR
k.A.
Tablets: Bilastinum 20 mg
Sandoz
Pharmaceuticals AG
D
FB
G
CM
Allerxtin Sandoz 20 mg
50
PR
PR
k.A.
Tablets: Bilastinum 20 mg
Sandoz
Pharmaceuticals AG
D
FB
G
IP
Progesterone LEMAN 100 mg
30
PR
PR
k.A.
Soft capsules: Progesteronum 100 mg
Leman SKL SA
B
FB
G
IP
Progesterone LEMAN 100 mg
90
PR
PR
k.A.
Soft capsules: Progesteronum 100 mg
Leman SKL SA
B
FB
G
IP
Progesterone LEMAN 200 mg
15
PR
PR
k.A.
Soft capsules: Progesteronum 200 mg
Leman SKL SA
B
FB
G
IP
Progesterone LEMAN 200 mg
45
PR
PR
k.A.
Soft capsules: Progesteronum 200 mg
Leman SKL SA
B
FB
G
Laurak 250 mg
30
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 250 mg
90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 250 mg
180
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 250 mg
2 x 90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 500 mg
30
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 500 mg
90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 500 mg
180
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 500 mg
2 x 90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 750 mg
30
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 750 mg
90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 750 mg
180
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 750 mg
2 x 90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1000 mg
30
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1000 mg
90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1000 mg
180
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1000 mg
2 x 90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1500 mg
30
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1500 mg
90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1500 mg
180
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Laurak 1500 mg
2 x 90
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg
Neuraxpharm
Switzerland AG
B
FB
G
Trabectedin Spirig HC
0,25 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trabectedinum
Spirig HealthCare AG
A
FB
G
Trabectedin Spirig HC 1 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trabectedinum 1 mg
Spirig HealthCare AG
A
FB
G
IP
CI
Sapropterin Spirig HC 100 mg
30
PR
PR
k.A.
Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg
Spirig HealthCare AG
B
FB
G
IP
CI
Sapropterin Spirig HC 100 mg
30
PR
PR
k.A.
Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg
Spirig HealthCare AG
B
FB
G
IP
CI
Sapropterin Spirig HC 100 mg
120
PR
PR
k.A.
Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg
Spirig HealthCare AG
B
FB
G
IP
CI
Sapropterin Spirig HC 100 mg
120
PR
PR
k.A.
Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg
Spirig HealthCare AG
B
FB
G
Allerino
10 ml
PR
PR
k.A.
Laboratoire
homéopathique D.
Schmidt-Nagel SA
D
FB
G
Calmolla
10 ml
PR
PR
k.A.
Laboratoire
homéopathique D.
Schmidt-Nagel SA
D
FB
G
Calmozen
10 ml
PR
PR
k.A.
Laboratoire
homéopathique D.
Schmidt-Nagel SA
D
FB
G
Digestola
10 ml
PR
PR
k.A.
Laboratoire
homéopathique D.
Schmidt-Nagel SA
D
FB
G
Frissela
10 ml
PR
PR
k.A.
Laboratoire
homéopathique D.
Schmidt-Nagel SA
D
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home